Cargando…
Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration
The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tum...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374624/ https://www.ncbi.nlm.nih.gov/pubmed/35044489 http://dx.doi.org/10.1007/s00262-022-03149-w |
_version_ | 1784767825895751680 |
---|---|
author | Kawaguchi, Sho Kawahara, Kenta Fujiwara, Yukio Ohnishi, Koji Pan, Cheng Yano, Hiromu Hirosue, Akiyuki Nagata, Masashi Hirayama, Masatoshi Sakata, Junki Nakashima, Hikaru Arita, Hidetaka Yamana, Keisuke Gohara, Shunsuke Nagao, Yuka Maeshiro, Manabu Iwamoto, Asuka Hirayama, Mayumi Yoshida, Ryoji Komohara, Yoshihiro Nakayama, Hideki |
author_facet | Kawaguchi, Sho Kawahara, Kenta Fujiwara, Yukio Ohnishi, Koji Pan, Cheng Yano, Hiromu Hirosue, Akiyuki Nagata, Masashi Hirayama, Masatoshi Sakata, Junki Nakashima, Hikaru Arita, Hidetaka Yamana, Keisuke Gohara, Shunsuke Nagao, Yuka Maeshiro, Manabu Iwamoto, Asuka Hirayama, Mayumi Yoshida, Ryoji Komohara, Yoshihiro Nakayama, Hideki |
author_sort | Kawaguchi, Sho |
collection | PubMed |
description | The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tumor effects of naringenin, which has been previously shown to activate CD169(+) macrophages, in a murine OSCC model. Immunohistochemical analysis for CD169 and CD8 was performed on lymph node and primary tumor specimens from 89 patients with OSCC. We also evaluated the effects of naringenin on two murine OSCC models. Increased CD169(+) macrophage counts in the regional lymph nodes correlated with favorable prognosis and CD8(+) cell counts within tumor sites. Additionally, naringenin suppressed tumor growth in two murine OSCC models. The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice. These results suggest that CD169(+) macrophages in lymph nodes are involved in T cell-mediated anti-tumor immunity and could be a prognostic marker for patients with OSCC. Moreover, naringenin is a new potential agent for CD169(+) macrophage activation in OSCC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03149-w. |
format | Online Article Text |
id | pubmed-9374624 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-93746242022-08-14 Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration Kawaguchi, Sho Kawahara, Kenta Fujiwara, Yukio Ohnishi, Koji Pan, Cheng Yano, Hiromu Hirosue, Akiyuki Nagata, Masashi Hirayama, Masatoshi Sakata, Junki Nakashima, Hikaru Arita, Hidetaka Yamana, Keisuke Gohara, Shunsuke Nagao, Yuka Maeshiro, Manabu Iwamoto, Asuka Hirayama, Mayumi Yoshida, Ryoji Komohara, Yoshihiro Nakayama, Hideki Cancer Immunol Immunother Original Article The CD169(+) macrophages in lymph nodes are implicated in cytotoxic T lymphocyte (CTL) activation and are associated with improved prognosis in several malignancies. Here, we investigated the significance of CD169(+) macrophages in oral squamous cell carcinoma (OSCC). Further, we tested the anti-tumor effects of naringenin, which has been previously shown to activate CD169(+) macrophages, in a murine OSCC model. Immunohistochemical analysis for CD169 and CD8 was performed on lymph node and primary tumor specimens from 89 patients with OSCC. We also evaluated the effects of naringenin on two murine OSCC models. Increased CD169(+) macrophage counts in the regional lymph nodes correlated with favorable prognosis and CD8(+) cell counts within tumor sites. Additionally, naringenin suppressed tumor growth in two murine OSCC models. The mRNA levels of CD169, interleukin (IL)-12, and C-X-C motif chemokine ligand 10 (CXCL10) in lymph nodes and CTL infiltration in tumors significantly increased following naringenin administration in tumor-bearing mice. These results suggest that CD169(+) macrophages in lymph nodes are involved in T cell-mediated anti-tumor immunity and could be a prognostic marker for patients with OSCC. Moreover, naringenin is a new potential agent for CD169(+) macrophage activation in OSCC treatment. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00262-022-03149-w. Springer Berlin Heidelberg 2022-01-19 2022 /pmc/articles/PMC9374624/ /pubmed/35044489 http://dx.doi.org/10.1007/s00262-022-03149-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Kawaguchi, Sho Kawahara, Kenta Fujiwara, Yukio Ohnishi, Koji Pan, Cheng Yano, Hiromu Hirosue, Akiyuki Nagata, Masashi Hirayama, Masatoshi Sakata, Junki Nakashima, Hikaru Arita, Hidetaka Yamana, Keisuke Gohara, Shunsuke Nagao, Yuka Maeshiro, Manabu Iwamoto, Asuka Hirayama, Mayumi Yoshida, Ryoji Komohara, Yoshihiro Nakayama, Hideki Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title_full | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title_fullStr | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title_full_unstemmed | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title_short | Naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node CD169-positive macrophage activation and cytotoxic T cell infiltration |
title_sort | naringenin potentiates anti-tumor immunity against oral cancer by inducing lymph node cd169-positive macrophage activation and cytotoxic t cell infiltration |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9374624/ https://www.ncbi.nlm.nih.gov/pubmed/35044489 http://dx.doi.org/10.1007/s00262-022-03149-w |
work_keys_str_mv | AT kawaguchisho naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT kawaharakenta naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT fujiwarayukio naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT ohnishikoji naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT pancheng naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT yanohiromu naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT hirosueakiyuki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT nagatamasashi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT hirayamamasatoshi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT sakatajunki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT nakashimahikaru naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT aritahidetaka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT yamanakeisuke naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT goharashunsuke naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT nagaoyuka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT maeshiromanabu naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT iwamotoasuka naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT hirayamamayumi naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT yoshidaryoji naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT komoharayoshihiro naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration AT nakayamahideki naringeninpotentiatesantitumorimmunityagainstoralcancerbyinducinglymphnodecd169positivemacrophageactivationandcytotoxictcellinfiltration |